Background. Antiplatelet therapy with aspirin is prevalent among patients presenting for operative treatment of pancreatic disorders. Operative practice has called for the cessation of aspirin 7-10 days before elective procedures because of the perceived increased risk of procedure-related bleeding. Our practice at Thomas Jefferson University has been to continue aspirin therapy throughout the perioperative period in patients undergoing elective pancreatic surgery. Study design. Records for patients undergoing pancreatoduodenectomy, distal pancreatectomy, or total pancreatectomy between October 2005 and February 2012 were queried for perioperative aspirin use in this institutional research board-approved retrospective study. Statistical analyses were performed with Stata software. Results. During the study period, 1,017 patients underwent pancreatic resection, of whom 289 patients (28.4%) were maintained on aspirin through the morning of the operation. Patients in the aspirin group were older than those not taking aspirin (median 69 years vs 62 years, P
CITATION STYLE
Wolf, A. M., Pucci, M. J., Gabale, S. D., McIntyre, C. A., Irizarry, A. M., Kennedy, E. P., … Yeo, C. J. (2014). Safety of perioperative aspirin therapy in pancreatic operations. In Surgery (United States) (Vol. 155, pp. 39–46). Mosby Inc. https://doi.org/10.1016/j.surg.2013.05.031
Mendeley helps you to discover research relevant for your work.